To evaluate the pathological response after degradable starch microspheres transarterial chemoembolization (DSM-TACE) conducted to bridge or downstage hepatocellular carcinoma (HCC) patients to liver transplantation.
To evaluate the pathological response after degradable starch microspheres transarterial chemoembolization (DSM-TACE) conducted to bridge or downstage hepatocellular carcinoma (HCC) patients to liver transplantation.